# US 2020/0347090 A1 · Cd73 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0347090 A1
- Document ID: US20200347090A1
- Status: Published application
- Kind: A1
- Application number: 16/760,380
- Filed: 2018-11-02
- Published: 2020-11-05
- Earliest claimed: 2017-11-03
- Assignees: Oric Pharmaceuticals, Inc.
- Applicants: ORIC Pharmaceuticals, Inc.
- Inventors: Xiaohui DU; John EKSTEROWICZ; Valeria R. FANTIN; Erica L. JACKSON; Daqing SUN; Qiuping YE; Jared MOORE; Tatiana ZAVOROTINSKAYA
- Web page: https://patentgrep.com/patent/US20200347090A1

## CPC

- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07H 19/23: Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 31/7064: containing condensed or non-condensed pyrimidines
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/12: Antivirals
- A61P 33/14: Ectoparasiticides, e.g. scabicides
- A61P 35/00: Antineoplastic agents
- C07F 9/65616: {containing the ring system [IMAGE cpc-sch-C07F-1006.gif] having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs}
- C07F 9/657181: {the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative}
- C07H 19/056: Triazole or tetrazole radicals
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

## Claims

### Claim 1

A compound of Formula (IIa), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
wherein:
A is —O— or —CH2—;
Q1 is CW and Q2 is N; or
Q1 is N and Q2 is N;
W is hydrogen, halogen, —CN, —OH, —ORa, —SH, —SRa, —S(═O)Ra, —NO2, —NRcRd, —S(═O)2Ra, —NHS(═O)2Ra, —S(═O)2NRcRd, —C(═O)Ra, —OC(═O)Ra, —C(═O)ORb, —OC(═O)ORb, —C(═O)NRcRd, —OC(═O)NRcRd, —NRbC(═O)NRcRd, —NRbC(═O)Ra, —NRbC(═O)ORb, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(aryl), C1-C6 alkyl(heteroaryl), C1-C6 alkyl(cycloalkyl), or C1-C6 alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30;
Z is —NR1R2, —OR60, —SR61, or —CR62R63R64;
R1 and R2 are each independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(aryl), C1-C6 alkyl(heteroaryl), C1-C6 alkyl(cycloalkyl), C1-C6 alkyl(heterocycloalkyl), —S(═O)2Ra, —S(═O)2NR6aR7a, or —C(═O)2R1a wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30a;
or R1 and R2 are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R30b;
R60 is hydrogen, —C(═O)R15e, —C(═O)OR16e, —C(═O)NR16eR17e, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(aryl), C1-C6 alkyl(heteroaryl), C1-C6 alkyl(cycloalkyl), C1-C6 alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30m;
R61 is hydrogen, —C(═O)R15f, —C(═O)OR16f, —C(═O)NR16fR17f, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(aryl), C1-C6 alkyl(heteroaryl), C1-C6 alkyl(cycloalkyl), C1-C6 alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30n;
R62, R63, and R64 are each independently hydrogen, halogen, —CN, —OH, —OR15g, —SH, —SR15g, —S(═O)R15g, —NO2, —NR16gR17g, —S(═O)2R15g, —NHS(═O)2R15g, —S(═O)2NR16gR17g, —C(═O)R15g, —OC(═O)R15g, —C(═O)OR16g, —OC(═O)OR16g, —C(═O)NR16gR17g, —OC(═O)NR16gR17g, —NR16gC(═O)NR16gR17g, —NR16gC(═O)R15g, —NR16gC(═O)OR16g, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(aryl), C1-C6 alkyl(heteroaryl), C1-C6 alkyl(cycloalkyl), or C1-C6 alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30o;
R3 is halogen, —CN, —OH, —OR15b, —SR18b, —NR16bR17b, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(aryl), C1-C6 alkyl(heteroaryl), C1-C6 alkyl(cycloalkyl), or C1-C6 alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30c;
R4 and R7 are each independently hydrogen, halogen, —OH, —OR15c, —NR16cS(═O)2R15c, —NR16cC(═O)R15c, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30d;
R5 and R6 are each independently hydrogen, halogen, —OH, —OR15d, —NR16dS(═O)2R15d, —NR16dC(═O)R15d, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30e;
X1 is a bond;
Y1 is —S(═O)2—;
Y2 is —(CR45R46)v2—;
R45 and R46 are each independently hydrogen, halogen, —OH, —ORa, —NRcRd, C1-C6 alkyl, or C1-C6 haloalkyl;
v2 is 1-3;
R15a, R15b, R15c, R15d, R15e, R15f, R15g are each independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30g;
R16a, R16b, R16c, R16d, R16e, R16f, R16g, R17a, R17b, R17e, R17f, and R17g are each independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R30h;
or R16a and R17a or R16b and R17b or R16e and R17e or R16f and R17f or R16g and R17g are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three halogen, C1-C6 alkyl, or C1-C6 haloalkyl;
R18b is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(aryl), C1-C6 alkyl(heteroaryl), C1-C6 alkyl(cycloalkyl), or C1-C6 alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R3;
R21 and R22 are each independently hydrogen, C1-C20 alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(aryl), C1-C6 alkyl(heteroaryl), C1-C6 alkyl(cycloalkyl), C1-C6 alkyl(heterocycloalkyl), —(CR23R24)wC(═O)OR25, —(CR23R24)wOC(═O)R26, (CR23R24)wSC(═O)R26, or —(CR23R24)wOC(═O)OR25; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30k;
or R21 and R22 are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R30l;
each R23 and R24 are independently hydrogen, halogen, —OH, —ORa, —NRcRd, C1-C6 alkyl, or C1-C6 haloalkyl;
each R25 is independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or C1-C6 heteroalkyl;
each R26 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or C1-C6 heteroalkyl;
each w is independently 1-4;
each R30, R30a, R30b, R30c, R30d, R30e, R30g, R30h, R30i, R30j, R30k, R30l, R30m, R30n, and R30o are independently halogen, —CN, —OH, —ORa, —SH, —SRa, —S(═O)Ra, —NO2, —NRcRd, —S(═O)2Ra, —NHS(═O)2Ra, —S(═O)2NRcRd, —C(═O)Ra, —OC(═O)Ra, —C(═O)ORb, —OC(═O)ORb, —C(═O)NRcRd, —OC(═O)NRcRd, —NRbC(═O)NRcRd, —NRbC(═O)Ra, —NRbC(═O)ORb, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(aryl), C1-C6 alkyl(heteroaryl), C1-C6 alkyl(cycloalkyl), or C1-C6 alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R31;
each R31 is independently halogen, —CN, —OH, —ORa, —SH, —SRa, —S(═O)Ra, —NO2, —NRcRd, —S(═O)2Ra, —NHS(═O)2Ra, —S(═O)2NRcRd, —C(═O)Ra, —OC(═O)Ra, —C(═O)ORb, —OC(═O)ORb, —C(═O)NRcRd, —OC(═O)NRcRd, —NRbC(═O)NRcRd, —NRbC(═O)Ra, —NRbC(═O)ORb, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 heteroalkyl, or cycloalkyl optionally substituted with one, two, or three halogen, C1-C6 alkyl, or C1-C6 haloalkyl;
each Ra is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three halogen, —OH, C1-C6 alkyl, or C1-C6 haloalkyl;
each Rb is independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three halogen, —OH, C1-C6 alkyl, or C1-C6 haloalkyl; and
Rc and Rd are each independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three halogen, —OH, C1-C6 alkyl, or C1-C6 haloalkyl;
or Rc and Rd are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three halogen, C1-C6 alkyl, or C1-C6 haloalkyl.

### Claim 2 (depends on 1)

The compound of claim 1, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R45 and R46 are each independently hydrogen, halogen, or C1-C6 alkyl; and
v2 is 1 or 2.

### Claim 3 (depends on 1, 2)

The compound of claim 1 or 2, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R45 and R46 are each hydrogen; and
v2 is 1.

### Claim 4 (depends on 1, 2, 3)

The compound of any one of claims 1-3, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
Q1 is CW; and
Q2 is N.

### Claim 5 (depends on 1, 2, 3)

The compound of any one of claims 1-3 pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
Q1 is N; and
Q2 is N.

### Claim 6 (depends on 1, 2, 3, 4)

The compound of any one of claims 1-4, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
W is hydrogen, halogen, —CN, —OH, —ORa, —NRcRd, —C(═O)ORb, —C(═O)NRcRd, C1-C6 alkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl, is independently optionally substituted with one, two, or three R3.

### Claim 7 (depends on 1, 2, 3, 4, 6)

The compound of any one of claims 1-4 or 6, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
W is hydrogen, halogen, —OH, —ORa, —NRcRd, C1-C6 alkyl, or C1-C6 haloalkyl.

### Claim 8 (depends on 1, 2, 3, 4, 6, 7)

The compound of any one of claims 1-4 or 6 or 7, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
W is hydrogen.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
A is —O—.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The compound of any one of claims 1-8, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
A is —CH2—.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The compound of any one of claims 1-10, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R5 and R6 are each independently hydrogen, halogen, C1-C6 alkyl, or cycloalkyl; wherein each alkyl and cycloalkyl is independently optionally substituted with one, two, or three R3.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The compound of any one of claims 1-11, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
each R30e is independently halogen or C1-C6 alkyl.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The compound of any one of claims 1-12, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R5 and R6 are each hydrogen.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The compound of any one of claims 1-13, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R4 and R7 are each independently hydrogen, halogen, —OH, —OR15c, —NR16cS(═O)2R15c, —NR16cC(═O)R15c, C1-C6 alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30d.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The compound of any one of claims 1-14, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
each R30a is independently halogen or C1-C6 alkyl.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The compound of any one of claims 1-15, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R4 and R7 are each independently hydrogen, halogen, —OH, —OR15c, —NR16cS(═O)2R15c, or —NR16cC(═O)R15c.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The compound of any one of claims 1-16, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R15c and R15d are each independently C1-C6 alkyl or C1-C6 haloalkyl; and
R16c and R16d are each independently hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The compound of any one of claims 1-17, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R15c and R15d are each independently C1-C6 alkyl; and
R16c and R16d are each independently hydrogen or C1-C6 alkyl.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The compound of any one of claims 1-18, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R4 and R7 are each independently hydrogen, halogen, or —OH.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The compound of any one of claims 1-19, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R4 and R7 are each independently halogen or —OH.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The compound of any one of claims 1-20, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R4 and R7 are each —OH.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The compound of any one of claims 1-21, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
Z is —NR1R2.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The compound of any of claims 1-22, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R1 is C1-C6 alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(aryl), C1-C6 alkyl(heteroaryl), C1-C6 alkyl(cycloalkyl), C1-C6 alkyl(heterocycloalkyl), —S(═O)2R15a, —S(═O)2NR16aR17a, or —C(═O)2Ra; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30a.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The compound of any of claims 1-23, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R15a is C1-C6 alkyl, aryl, or C1-C6 alkyl(aryl); wherein each alkyl and aryl is optionally substituted with one, two, or three halogen; and
R16a and R17a are each independently hydrogen, C1-C6 alkyl, aryl, or C1-C6 alkyl(aryl); wherein each alkyl and aryl is optionally substituted with one, two, or three halogen; and

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The compound of any of claims 1-24, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R15a is C1-C6 alkyl; and
R16a and R17a are each independently hydrogen or C1-C6 alkyl.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The compound of any one of claims 1-25, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R1 is C1-C6 alkyl, cycloalkyl, C1-C6 alkyl(aryl), C1-C6 alkyl(heteroaryl), C1-C6 alkyl(cycloalkyl), or C1-C6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30a.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The compound of any one of claims 1-26, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R1 is C1-C6 alkyl, cycloalkyl, or C1-C6 alkyl(aryl); wherein each alkyl, cycloalkyl, and aryl is independently optionally substituted with one, two, or three R30a.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The compound of any one of claims 1-27, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R1 is cycloalkyl or C1-C6 alkyl(aryl); wherein each alkyl, cycloalkyl, and aryl is independently optionally substituted with one, two, or three R30a.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The compound of any one of claims 1-28, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
each R30a is independently halogen, —CN, —OH, —ORa, —NRcRd, —C(═O)ORb, —C(═O)NRcRd, C1-C6 alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R31.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The compound of any one of claims 1-29, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
each R31 is independently halogen or C1-C6 alkyl.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The compound of any one of claims 1-30, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
each R30a is independently halogen, —CN, —OH, —ORa, C1-C6 alkyl, or C1-C6 haloalkyl.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The compound of any one of claims 1-31, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
each R30a is independently halogen.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The compound of any one of claims 1-32, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R2 is hydrogen or C1-C6 alkyl.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The compound of any one of claims 1-25, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R1 and R2 are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R30b.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 34)

The compound of any one of claims 1-25 or 34, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R1 and R2 are taken together with the nitrogen atom to which they are attached to form a piperidine or a pyrrolidine optionally substituted with one, two, or three R30b.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 34, 35)

The compound of any one of claims 1-25 or 34 or 35, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
each R30b is independently aryl optionally substituted with one, two, or three R31; and
each R31 is independently halogen, C1-C6 alkyl, or C1-C6 haloalkyl.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 34, 35, 36)

The compound of any one of claims 1-25 or 34-36, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R30b is aryl.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The compound of any one of claims 1-37, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R3 is halogen, —CN, —SR18b, C1-C6 alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(aryl), C1-C6 alkyl(heteroaryl), C1-C6 alkyl(cycloalkyl), or C1-C6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30c.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The compound of any one of claims 1-38, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R3 is halogen, —CN, —SR18b, C1-C6 alkyl, or C1-C6 alkyl(cycloalkyl); wherein each alkyl, and cycloalkyl is independently optionally substituted with one, two, or three R3.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The compound of any one of claims 1-39, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R18b is cycloalkyl or C1-C6 alkyl(cycloalkyl).

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The compound of any one of claims 1-40, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
each R30c is independently halogen or C1-C6 alkyl.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The compound of any one of claims 1-38, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R3 is halogen.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The compound of any one of claims 1-42, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R21 and R22 are each independently hydrogen, aryl, or —(CR23R24)wOC(═O)OR25.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The compound of any one of claims 1-43, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R21 and R22 are each hydrogen.

### Claim 45 (depends on 1)

The compound of claim 1, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, selected from:

### Claim 46

A compound of Formula (III), or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof:
wherein:
Q3 and Q4 are independently N or CW1; provided that at least one of Q3 or Q4 is N;
W1 is hydrogen, halogen, —CN, —OH, —ORa, C1-C6 alkyl, or C1-C6 haloalkyl;
A is —O— or —CH2—;
Z is —NR1R2, —OR60, —SR61, or —CR62R63R64;
R1 and R2 are each independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(aryl), C1-C6 alkyl(heteroaryl), C1-C6 alkyl(cycloalkyl), C1-C6 alkyl(heterocycloalkyl), —S(═O)2R15a, —S(═O)2NR16aR17a, or —C(═O)2R15a wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30a;
or R1 and R2 are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R30b;
R60 is hydrogen, —C(═O)R15e, —C(═O)OR16e, —C(═O)NR16eR17e, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(aryl), C1-C6 alkyl(heteroaryl), C1-C6 alkyl(cycloalkyl), C1-C6 alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30m;
R61 is hydrogen, —C(═O)R15f, —C(═O)OR16f, —C(═O)NR16fR17f, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(aryl), C1-C6 alkyl(heteroaryl), C1-C6 alkyl(cycloalkyl), C1-C6 alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30n;
R62, R63, and R64 are each independently hydrogen, halogen, —CN, —OH, —OR15g, —SH, —SR15g, —S(═O)R15g, —NO2, —NR16gR17g, —S(═O)2R15g, —NHS(═O)2R15g, —S(═O)2NR16gR17g, —C(═O)R15g, —OC(═O)R15g, —C(═O)OR16g, —OC(═O)OR16g, —C(═O)NR16gR17g, —OC(═O)NR16gR17g, —NR16gC(═O)NR16gR17g, —NR16gC(═O)R15g, —NR16gC(═O)OR16g, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(aryl), C1-C6 alkyl(heteroaryl), C1-C6 alkyl(cycloalkyl), or C1-C6 alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30o;
R3 is halogen, —CN, —OH, —OR15b, —SR18b, —NR16bR17b, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(aryl), C1-C6 alkyl(heteroaryl), C1-C6 alkyl(cycloalkyl), or C1-C6 alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30o;
R4 and R7 are each independently hydrogen, halogen, —OH, —OR15c, —NR16cS(═O)2R15c, —NR16cC(═O)R15c, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30d;
R5 and R6 are each independently hydrogen, halogen, —OH, —OR15d, NR16dS(═O)2R15d, —NR16dC(═O)Rid, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30e;
R8 is hydrogen, halogen, —OH, —ORa, —NRcRd, C1-C6 alkyl, or C1-C6 haloalkyl;
R9 and R10 are each independently hydrogen, halogen, C1-C6 alkyl, or C1-C6 haloalkyl;
X1 is bond, —C(═O)—, —S(═O)2—, —O—, or —CR40R41—;
Y1 is —C(═O)—, —(CR42R43)v1—, —S(═O)2—, —NR44—, —S—, or —O—;
Y2 is —(CR45R46)v2—, —NR47—, or —O—;
R40, R41, R42, R43, R45, and R46 are each independently hydrogen, halogen, —OH, —ORa, —NRcRd, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R30p;
R44 and R47 are each independently hydrogen, —S(═O)Ra, —S(═O)2Ra, —S(═O)2NRcRd, —C(═O)Ra, —C(═O)ORb, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R30f;
v1 and v2 are each independently 1-3;
R15a, R15b, R15c, R15d, R15e, R15f, R15g are each independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30g;
R16a, R16b, R16c, R16d, R16e, R16f, R16g, R17a, R17b, R17e, R17f, and R17g are each independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R30h;
or R16a and R17a or R16b and R17b or R16e and R17e or R16f and R17f or R16g and R17g are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three halogen, C1-C6 alkyl, or C1-C6 haloalkyl;
R18b is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(aryl), C1-C6 alkyl(heteroaryl), C1-C6 alkyl(cycloalkyl), or C1-C6 alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30i;
R21 and R22 are each independently hydrogen, C1-C20 alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(aryl), C1-C6 alkyl(heteroaryl), C1-C6 alkyl(cycloalkyl), C1-C6 alkyl(heterocycloalkyl), —(CR23R24)wC(═O)OR25, —(CR23R24)wOC(═O)R26, —(CR23R24)wSC(═O)R26, or —(CR23R24)wOC(═O)OR25; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30k;
or R21 and R22 are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R30l;
each R23 and R24 are independently hydrogen, halogen, —OH, —ORa, —NRcRd, C1-C6 alkyl, or C1-C6 haloalkyl;
each R25 is independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or C1-C6 heteroalkyl;
each R26 is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or C1-C6 heteroalkyl;
each w is independently 1-4;
each R30a, R30b, R30c, R30d, R30e, R30f, R30g, R30h, R30i, R30j, R30k, R30l, R30m, R30n, R30o, and R30p are independently halogen, —CN, —OH, —ORa, —SH, —SRa, —S(═O)Ra, —NO2, —NRcRd, —S(═O)2Ra, —NHS(═O)2Ra, —S(═O)2NRcRd, —C(═O)Ra, —OC(═O)Ra, —C(═O)ORb, —OC(═O)ORb, —C(═O)NRcRd, —OC(═O)NRcRd, —NRbC(═O)NRcRd, —NRbC(═O)Ra, —NRbC(═O)ORb, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(aryl), C1-C6 alkyl(heteroaryl), C1-C6 alkyl(cycloalkyl), or C1-C6 alkyl(heterocycloalkyl); wherein each alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R31;
each R31 is independently halogen, —CN, —OH, —ORa, —SH, —SRa, —S(═O)Ra, —NO2, —NRcRd, —S(═O)2Ra, —NHS(═O)2Ra, —S(═O)2NRcRd, —C(═O)Ra, —OC(═O)Ra, —C(═O)ORb, —OC(═O)ORb, —C(═O)NRcRd, —OC(═O)NRcRd, —NRbC(═O)NRcRd, —NRbC(═O)Ra, —NRbC(═O)ORb, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 heteroalkyl, or cycloalkyl optionally substituted with one, two, or three halogen, C1-C6 alkyl, or C1-C6 haloalkyl;
each Ra is independently C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three halogen, —OH, C1-C6 alkyl, or C1-C6 haloalkyl;
each Rb is independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three halogen, —OH, C1-C6 alkyl, or C1-C6 haloalkyl; and
Rc and Rd are each independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three halogen, —OH, C1-C6 alkyl, or C1-C6 haloalkyl;
or Rc and Rd are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three halogen, C1-C6 alkyl, or C1-C6 haloalkyl.

### Claim 47 (depends on 46)

The compound of claim 46, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:

### Claim 48 (depends on 46, 47)

The compound of claim 46 or 47, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:

### Claim 49 (depends on 46, 47, 48)

The compound of any one of claims 46-48, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:

### Claim 50 (depends on 46, 47, 48)

The compound of any one of claims 46-48, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:

### Claim 51 (depends on 46, 47, 48, 49, 50)

The compound of any one of claims 46-50, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
Q3 is N and Q4 is CW1.

### Claim 52 (depends on 46, 47, 48, 49, 50)

The compound of any one of claims 46-50, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
Q4 is N and Q3 is CW1.

### Claim 53 (depends on 46, 47, 48, 49, 50)

The compound of any one of claims 46-50, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
Q3 is N and Q4 is N.

### Claim 54 (depends on 46, 47, 48, 49, 50, 51, 52, 53)

The compound of any one of claims 46-53, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
W1 is hydrogen, halogen, or C1-C6 alkyl.

### Claim 55 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54)

The compound of any one of claims 46-54, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R8 is hydrogen or C1-C6 alkyl.

### Claim 56 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The compound of any one of claims 46-55, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R8 is hydrogen.

### Claim 57 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The compound of any one of claims 46-56, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R9 and R10 are each independently hydrogen or C1-C6 alkyl.

### Claim 58 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The compound of any one of claims 46-57, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R9 and R10 are each hydrogen.

### Claim 59 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The compound of any one of claims 46-58, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R40 and R41 are each independently hydrogen, halogen, —OH, —ORa, —NRcRd, C1-C6 alkyl, or C1-C6 haloalkyl.

### Claim 60 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The compound of any one of claims 46-59, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R40 and R41 are each independently hydrogen, halogen, —OH, C1-C6 alkyl, or C1-C6 haloalkyl.

### Claim 61 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The compound of any one of claims 46-60, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R40 and R41 are each hydrogen.

### Claim 62 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The compound of any one of claims 46-61, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R42 and R43 are each independently hydrogen, halogen, —OH, —ORa, or C1-C6 alkyl.

### Claim 63 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The compound of any one of claims 46-62, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R42 and R43 are each hydrogen.

### Claim 64 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The compound of any one of claims 46-63, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R44 is hydrogen, —S(═O)2Ra, —C(═O)Ra, C1-C6 alkyl, C1-C6 haloalkyl, or C1-C6 alkyl(aryl).

### Claim 65 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The compound of any one of claims 46-64, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R44 is hydrogen or C1-C6 alkyl.

### Claim 66 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The compound of any one of claims 46-65, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R45 and R6 are each independently hydrogen, halogen, —OH, —ORa, —NRcRd, C1-C6 alkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R30p.

### Claim 67 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The compound of any one of claims 46-66, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R45 and R46 are each independently hydrogen, halogen, C1-C6 alkyl, or cycloalkyl; wherein each alkyl and cycloalkyl is independently optionally substituted with one, two, or three R3.

### Claim 68 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The compound of any one of claims 46-67, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R45 and R46 are each independently hydrogen, halogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C1-C6 alkyl(cycloalkyl), C1-C6 alkyl(aryl), or cycloalkyl.

### Claim 69 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The compound of any one of claims 46-68, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R45 and R46 are each independently hydrogen or C1-C6 alkyl.

### Claim 70 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)

The compound of any one of claims 46-69, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R45 and R46 are each hydrogen.

### Claim 71 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The compound of any one of claims 46-67, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R45 is halogen, —OH, —ORa, —NRcRd, C1-C6 alkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R30p; and
R46 is hydrogen or C1-C6 alkyl.

### Claim 72 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 71)

The compound of any one of claims 46-67 or 71, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R45 is halogen, C1-C6 alkyl, or cycloalkyl; wherein each alkyl and cycloalkyl is independently optionally substituted with one, two, or three R30p; and
R46 is hydrogen or C1-C6 alkyl.

### Claim 73 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 71, 72)

The compound of any one of claims 46-67 or 71 or 72, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R45 is halogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C1-C6 alkyl(cycloalkyl), C1-C6 alkyl(aryl), or cycloalkyl; and
R46 is hydrogen or C1-C6 alkyl.

### Claim 74 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 71, 72, 73)

The compound of any one of claims 46-67 or 71-73, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R45 is C1-C6 alkyl; and
R46 is hydrogen or C1-C6 alkyl.

### Claim 75 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The compound of any one of claims 46-74, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
A is —O—.

### Claim 76 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The compound of any one of claims 46-74, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
A is —CH2—.

### Claim 77 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The compound of any one of claims 46-76, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R5 and R6 are each independently hydrogen, halogen, C1-C6 alkyl, or cycloalkyl; wherein each alkyl and cycloalkyl is independently optionally substituted with one, two, or three R3.

### Claim 78 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The compound of any one of claims 46-77, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
each R30e is independently halogen or C1-C6 alkyl.

### Claim 79 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The compound of any one of claims 46-78, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R5 and R6 are each hydrogen.

### Claim 80 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

The compound of any one of claims 46-79, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R4 and R7 are each independently hydrogen, halogen, —OH, —OR15c, —NR16cS(═O)2R15c, —NR16cC(═O)R15, C1-C6 alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30d.

### Claim 81 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80)

The compound of any one of claims 46-80, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
each R30a is independently halogen or C1-C6 alkyl.

### Claim 82 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80)

The compound of any one of claims 46-80, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R4 and R7 are each independently hydrogen, halogen, —OH, —OR15c, —NR16cS(═O)2R15, or —NR16cC(═O)R15c.

### Claim 83 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The compound of any one of claims 46-82, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R15c and R15d are each independently C1-C6 alkyl or C1-C6 haloalkyl; and
R16c and R16d are each independently hydrogen, C1-C6 alkyl, or C1-C6 haloalkyl.

### Claim 84 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)

The compound of any one of claims 46-83, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R15c and R15d are each independently C1-C6 alkyl; and
R16c and R16d are each independently hydrogen or C1-C6 alkyl.

### Claim 85 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84)

The compound of any one of claims 46-84, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R4 and R7 are each independently hydrogen, halogen, or —OH.

### Claim 86 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85)

The compound of any one of claims 46-85, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R4 and R7 are each independently halogen or —OH.

### Claim 87 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86)

The compound of any one of claims 46-86, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R4 and R7 are each —OH.

### Claim 88 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87)

The compound of any one of claims 46-87, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
Z is —NR1R2.

### Claim 89 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88)

The compound of any one of claims 46-88, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R1 is C1-C6 alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(aryl), C1-C6 alkyl(heteroaryl), C1-C6 alkyl(cycloalkyl), or C1-C6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30a.

### Claim 90 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The compound of any one of claims 46-89, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R1 is C1-C6 alkyl, cycloalkyl, heterocycloalkyl, C1-C6 alkyl(aryl), C1-C6 alkyl(heteroaryl), C1-C6 alkyl(cycloalkyl), or C1-C6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R30a.

### Claim 91 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90)

The compound of any one of claims 46-90, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R1 is C1-C6 alkyl, cycloalkyl, or C1-C6 alkyl(aryl); wherein each alkyl, cycloalkyl, and aryl is independently optionally substituted with one, two, or three R30a.

### Claim 92 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91)

The compound of any one of claims 46-91, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R1 is cycloalkyl or C1-C6 alkyl(aryl); wherein each alkyl, cycloalkyl, and aryl is independently optionally substituted with one, two, or three R30a.

### Claim 93 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92)

The compound of any one of claims 46-92, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
each R30a is independently halogen, —CN, —OH, —ORa, —NRcRd, —C(═O)ORb, —C(═O)NRcRd, C1-C6 alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R31.

### Claim 94 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93)

The compound of any one of claims 46-93, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
each R30a is independently halogen, —CN, —OH, —ORa, C1-C6 alkyl, or C1-C6 haloalkyl.

### Claim 95 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94)

The compound of any one of claims 46-94, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
each R30a is independently halogen.

### Claim 96 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

The compound of any one of claims 46-95, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R2 is hydrogen or C1-C6 alkyl.

### Claim 97 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88)

The compound of any one of claims 46-88, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R1 and R2 are taken together with the nitrogen atom to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R30b.

### Claim 98 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 97)

The compound of any one of claims 46-88 or 97, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R1 and R2 are taken together with the nitrogen atom to which they are attached to form an azetidine, a piperidine, a morpholine, or a pyrrolidine optionally substituted with one, two, or three R30b.

### Claim 99 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The compound of any one of claims 46-98, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R3 is halogen, —CN, —OR5b, —SR18b, —NR16bR17b, C1-C6 alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6 alkyl(aryl), C1-C6 alkyl(heteroaryl), C1-C6 alkyl(cycloalkyl), or C1-C6 alkyl(heterocycloalkyl); wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R3.

### Claim 100 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99)

The compound of any one of claims 46-99, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R3 is halogen, —CN, —OR15b, —NR16bR17b, C1-C6 alkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one, two, or three R30c.

### Claim 101 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100)

The compound of any one of claims 46-100, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R15b is C1-C6 alkyl.

### Claim 102 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101)

The compound of any one of claims 46-101, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R16b and R17b are independently hydrogen or is C1-C6 alkyl.

### Claim 103 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102)

The compound of any one of claims 46-102, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
each R30c is independently halogen or C1-C6 alkyl.

### Claim 104 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103)

The compound of any one of claims 46-103, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R3 is halogen.

### Claim 105 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104)

The compound of any one of claims 46-104, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R21 and R22 are each independently hydrogen, aryl, or —(CR23R24)wOC(═O)OR25.

### Claim 106 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105)

The compound of any one of claims 46-105, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R21 and R22 are each hydrogen.

### Claim 107 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106)

The compound of any one of claims 46-106, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R21 and R22 are taken together with the atoms to which they are attached to form a heterocycloalkyl optionally substituted with one, two, or three R30l.

### Claim 108 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107)

The compound of any one of claims 46-107, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R30l is C1-C6 alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein each alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one, two, or three R31.

### Claim 109 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108)

The compound of any one of claims 46-108, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R30l is aryl optionally substituted with one, two, or three R31.

### Claim 110 (depends on 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109)

The compound of any one of claims 46-109, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
each R31 is independently halogen or C1-C6 alkyl.

### Claim 111 (depends on 46)

The compound of claim 46, pharmaceutically acceptable salt, solvate, or stereoisomer thereof, selected from:

### Claim 112 (depends on 1, 111)

A pharmaceutical composition comprising a compound of any one of claims 1-111, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and a pharmaceutically acceptable excipient.

### Claim 113 (depends on 1, 111)

A method of inhibiting CD73 comprising contacting CD73 with a compound of any one of claims 1-111, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

### Claim 114 (depends on 1, 111)

A method of treating cancer in a subject, comprising administering to the subject a compound of any one of claims 1-111, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

### Claim 115 (depends on 112)

A method of treating cancer in a subject, comprising administering to the subject a pharmaceutical composition of claim 112.

### Claim 116 (depends on 114, 115)

The method of either of claims 114 or 115, wherein the cancer is lung cancer, melanoma, breast cancer, ovarian cancer, colorectal cancer, gastric cancer, gallbladder cancer, prostate cancer, renal cancer, or a lymphoma.

### Claim 117 (depends on 113, 114, 115, 116)

The method of any one of claims 113-116, further comprising administering a second therapeutic agent.

### Claim 118 (depends on 117)

The method of claim 117, wherein the second therapeutic agent is a chemotherapeutic agent or an immunotherapy agent.

### Claim 119 (depends on 1, 111)

A method of treating an infection in a subject, comprising administering to the subject a compound of any one of claims 1-111, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

### Claim 120 (depends on 112)

A method of treating an infection in a subject, comprising administering to the subject a pharmaceutical composition of claim 112.

### Claim 121 (depends on 119, 120)

The method of either of claims 119 or 120, wherein the infection is a viral infection.

### Claim 122 (depends on 119, 120)

The method of either of claims 119 or 120, wherein the infection is a parasitic infection.

### Claim 123 (depends on 1, 111)

A method of treating a neurodegenerative disease in a subject, comprising administering to the subject a compound of any one of claims 1-111, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

### Claim 124 (depends on 112)

A method of treating a neurodegenerative disease in a subject, comprising administering to the subject a pharmaceutical composition of claim 112.

### Claim 125 (depends on 123, 124)

The method of either of claims 123 or 124, wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, Huntington's disease, schizophrenia, or autism.
